Skip to content

Baseline Dopamine Dependent Drug Effects of Methylphenidate and Sulpiride on Brain and Behaviour: A PET, Pharmaco-fMRI Study

Baseline Dopamine Dependent Drug Effects of Methylphenidate and Sulpiride on Brain and Behaviour: A PET, Pharmaco-fMRI Study - Baseline dopamine and cognition

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON43196
Enrollment
100
Registered
2016-09-27
Start date
2017-02-10
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

distractability lack of motivation

Interventions

None listed

Sponsors

Radboud Universiteit Nijmegen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy volunteers between 18 and 45 years of age

Exclusion criteria

Exclusion criteria: Neuropsychiatric disorders; history of drug abuse; heart problems; metal objects in or around the body (see section 4.3 in research protocol (C1) for full list of exclusion criteria)

Design outcomes

Primary

MeasureTime frame
Baseline dopamine synthesis capacity measured with [18F]-DOPA PET; BOLD signal measured with fMRI; behavioural performance on computerized tasks (measuring reward sensitivity, working memory, reversal learning, reinforcement learning, cognitive effort, the influence of affective information on goal-oriented behaviour, and creativity); subjective measurements (e.g. self-report questionnaires, visual analogue scales); psychophysiological recordings (e.g., blood pressure, heart rate, respiration, elctrocardiography); blood and saliva sample to assess dopamine genes for pathway-based genetics analysis.

Secondary

MeasureTime frame
All tasks in the cognitive testing battery (computerized tasks) result in both outcomes of primary interest (see section 7.1.1 in the study protocol) and additional outcomes (see section 7.1.2 in the study protocol). Our secondary objective is to further our understanding of the relationship between baseline dopamine synthesis capacity and baseline measures - such as working memory, genetic differences, impulsivity and eye-blink rate * to assess how baseline levels of dopamine mediate the effects of the drug on the secondary outcomes from the cognitive testing battery.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Feb 4, 2026